The first evaluates the benefit of epacadostat as an IDO1 inhibitor plus pembrolizumab in combination to treat patients with gastroesophageal junction cancer or GC, and the second evaluates the efficiency of BMS-986205 for the treatment of advanced GC [146]. Here, IDO1 is linked to gastric cancer.